Business Context and Reporting Period
This Form 8-K Current Report, filed on October 4, 2021, covers events occurring between September 28 and October 4, 2021, for LifeMD, Inc. (LFMD). The filing details the entry into material definitive agreements for two simultaneous capital raising transactions: a Common Stock Offering and a Series A Preferred Stock Offering, both underwritten by B. Riley Securities, Inc.
Key Financial Metrics and Capital Structure
The filing reports the following capital raise metrics:
- Common Stock Offering: Sale of 3,833,334 shares (including 500,000 shares pursuant to an option) at $6.00 per share. Net proceeds to the Company were approximately $16.4 million after deducting underwriting discounts, commissions, debt repayment, and offering expenses.
- Preferred Stock Offering: Sale of 1,400,000 shares of Series A Cumulative Perpetual Preferred Stock (plus an option for 210,000 additional shares) at $25.00 per share. Net proceeds to the Company were approximately $22.9 million after deducting underwriting discounts, commissions, structuring fees, debt repayment, and offering expenses.
- Total Net Proceeds: Approximately $39.3 million combined from both offerings.
- Debt Repayment: A portion of the proceeds from both offerings was utilized for the repayment of existing debt, though specific pre-offering debt balances are not disclosed in this text.
Material Changes and Security Rights
The filing discloses material modifications to the rights of security holders via the issuance of Series A Preferred Stock:
- Dividend Rights: Holders are entitled to cumulative cash dividends at a rate of 8.875% of the $25.00 liquidation preference per year ($2.21875 per share), payable quarterly in arrears beginning January 15, 2022.
- Liquidation Preference: The Series A Preferred Stock ranks senior to all common stock and other equity securities (except Series B Preferred Stock), on parity with Series B Preferred Stock, and junior to all indebtedness.
- Redemption Terms: The Company has the option to redeem the shares at a declining premium over time: $25.75 per share (Oct 2022–2023), $25.50 (Oct 2023–2024), $25.25 (Oct 2024–2025), and $25.00 thereafter, plus accrued dividends.
- Lock-Up Agreements: The Company and its directors/officers agreed not to sell common stock for 90 days following September 28, 2021, and not to sell preferred stock for 30 days following September 29, 2021, without underwriter consent.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue forecasts, or management commentary regarding future operational performance. It includes a standard cautionary note regarding forward-looking statements, noting that actual results may differ due to risks and uncertainties. The primary focus of the outlook is the use of proceeds to repay debt and fund general corporate purposes, though specific allocation percentages are not detailed in this summary text.
Investor Verification Checklist
- Verify the exact amount of debt repaid using the proceeds, as the filing states debt repayment occurred but does not quantify the specific principal amount retired.
- Confirm the total number of Series A Preferred Shares issued, including whether the underwriters exercised the option to purchase the additional 210,000 shares.
- Review the full Certificate of Designation (Exhibit 3.1) for detailed terms regarding voting rights and specific change-of-control redemption triggers.
- Check subsequent filings to confirm the first dividend payment date and amount in January 2022.
- Assess the impact of the 8.875% cumulative dividend obligation on future cash flow requirements.